Shire gambit aimed at delaying generic Adderall XR

Seeking to protect its market for the hyperactivity drug Adderall XR, Shire Pharmaceuticals filed a Citizens Petition asking regulators to require any generic competitor to demonstrate its equal effectiveness from the patient's perspective. That kind of testing requirement would likely delay any approval of a copycat competitor. A group of generic drug makers, including Teva, have filed abbreviated new drug applications for generic Adderall XR. Adderall XR represents half of Shire's annual sales revenue.

- read this report from AFX for more